Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Fineline Cube Apr 27, 2026
Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Fineline Cube Apr 27, 2026
Company Drug

Kanghong’s KH617 Receives Orphan Drug Designation for Glioblastoma

Fineline Cube Feb 16, 2023

China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving an Orphan Drug...

Company Drug

Luye Pharma’s BA2101 Begins Phase I Clinical Trial for Allergic Diseases

Fineline Cube Feb 16, 2023

China-based Luye Pharma Group (HKG: 2186) has announced the first subject dosing in a Phase...

Company Drug

CDE Accepts Clinical Trial Filing for Ranok’s First-in-Class BRD4 Degradation Drug RNK05047

Fineline Cube Feb 16, 2023

The Center for Drug Evaluation (CDE) website indicates that a clinical trial filing for RNK05047,...

Company Drug

Junshi Biosciences and Coherus Report Positive JUPITER-02 Trial Results for NPC Treatment

Fineline Cube Feb 16, 2023

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) and its US partner Coherus BioSciences...

Company Deals

Eyenovia Partners with Formosa Pharmaceuticals for Ophthalmic Therapeutics

Fineline Cube Feb 16, 2023

US-based Eyenovia Inc., (NASDAQ: EYEN) has announced a strategic development and collaboration agreement with Taiwan-based...

Company Deals

Brii Biosciences Publishes Positive Phase II Results for HBV Treatment

Fineline Cube Feb 15, 2023

China’s Brii Biosciences (HKG: 2137) has announced the publication of interim results from a Phase...

Company Drug

Hengrui Pharmaceuticals Gains NMPA Approval for SHR-A1921 Clinical Study

Fineline Cube Feb 15, 2023

Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving the go-ahead from the National Medical Products...

Company Medical Device

Grand Pharma Completes First Atrial Fibrillation Treatment with HeartLight X3

Fineline Cube Feb 15, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the successful completion of the first...

Company Drug

Zelgen’s ZG2001 and ZG0895 Clinical Trials Approved by NMPA

Fineline Cube Feb 15, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that separate clinical trial filings for...

Company Drug

Innovent Biologics Initiates Phase II Study for IBI311 in Thyroid-Associated Ophthalmopathy

Fineline Cube Feb 15, 2023

China-based Innovent Biologics Inc., (HKG: 1801) has announced the first patient dosing in a Phase...

Company Deals

Hygea Medtech Secures Series D Funding for Oncology Device Expansion

Fineline Cube Feb 15, 2023

Hygea Medical Technology Co., Ltd, a leading minimally invasive device maker for oncology indications based...

Company Deals

CTI Acquires Vectoring Pharmatech to Expand Pharmacy CMC Research

Fineline Cube Feb 15, 2023

China-based Centre Testing International Group Co., Ltd (CTI), a leading third-party testing and qualification services...

Company Deals

Shenzhen United Family Hospital Partners with GBA Medical Delegation

Fineline Cube Feb 15, 2023

Shenzhen United Family Hospital has struck a partnership with a medical delegation from the Guangdong-Hong...

Company Deals

Vincentage Raises RMB 100 Million for Innovative Drug Development

Fineline Cube Feb 15, 2023

Suzhou-based new drug developer Vincentage has reportedly raised close to RMB 100 million (USD 14.6...

Company Deals

Sequanta and Grandomics Collaborate on Ultra-High Throughput Sequencing Lab

Fineline Cube Feb 15, 2023

Sequanta Technologies, a multi-omics research and clinical service provider based in Shanghai, and Grandomics Biosciences...

Company Deals

Luzhu Biotech Files for IPO in Hong Kong, Sponsored by CICC

Fineline Cube Feb 15, 2023

Beijing Luzhu Biotechnology Co., Ltd, a leading human vaccine and therapeutic biologics maker, has made...

Policy / Regulatory

China’s NRDL Update: New Drugs Available for Online Procurement

Fineline Cube Feb 15, 2023

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) drug procurement platform has released a notice stating that...

Company Medical Device

Mindray Launches First Wireless Handheld Ultrasound System, TE Air

Fineline Cube Feb 15, 2023

China-based medical device firm Mindray (SHE: 300760) has announced the market launch of the firm’s...

Company Deals

Harbour BioMed Licenses HBM7008 to Cullinan Oncology for US Development

Fineline Cube Feb 14, 2023

Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China,...

Company Drug

Kangtai Biological Begins Phase I Trial for Tetravalent Influenza Vaccine

Fineline Cube Feb 14, 2023

China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the first subject enrollment...

Posts pagination

1 … 554 555 556 … 657

Recent updates

  • Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU
  • Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104
  • Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B
  • CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers
  • Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Novartis Wins CHMP Positive Opinion for Itvisma (Intrathecal Onasemnogene Abeparvovec) in 5q Spinal Muscular Atrophy Across All Ages in EU

Company Drug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Company Drug

Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B

Company Drug

CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.